Related Experiment Videos
Bayesian approach to evaluation of bridging studies.
Jen-pei Liu1, Chin-Fu Hsiao, Hueymiin Hsueh
1Department of Statistics, National Cheng-Kung University, Tainan, Taiwan. jpliu@nhri.org.tw
Journal of Biopharmaceutical Statistics
|November 27, 2002
Summary
This study introduces an empirical Bayesian approach to analyze bridging study data, enabling the assessment of clinical data similarity between regions. Sample size for bridging studies depends on original region efficacy evidence and patient allocation.
Area of Science:
- Clinical trial methodology
- Biostatistics
- Pharmaceutical regulatory science
Background:
- Bridging studies are crucial for extrapolating foreign clinical data to new regions post-product approval.
- Existing data from original regions provide established efficacy and safety profiles.
- Assessing regional similarity is vital for regulatory submissions.
Purpose of the Study:
- To propose a statistical method for analyzing bridging study data.
- To evaluate the similarity of clinical data between a new and an original region.
- To suggest a sample size determination method for bridging studies.
Main Methods:
- Utilizing an empirical Bayesian approach to synthesize data from bridging and original regions.
- Developing a statistical framework for assessing regional data similarity.
- Proposing a sample size calculation method for bridging trials.
Main Results:
- The empirical Bayesian approach effectively synthesizes diverse clinical data.
- The proposed method allows for robust assessment of regional similarity.
- Sample size is inversely proportional to original efficacy evidence and test product allocation proportion.
Conclusions:
- The empirical Bayesian method offers a robust approach for bridging study data analysis.
- This methodology facilitates the extrapolation of foreign clinical data.
- The sample size determination method aids in efficient trial design.